CTXR News and Press, Citius Pharmaceuticals Inc. From 11/09/23

Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 PR Newswire CRANFORD, N.J. , Nov. 9, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company de...

Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor PR Newswire Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tu...

2023-10-24 09:23:34 ET More on Citius Citius Pharmaceuticals: Not A Lot Of Cash Left Ahead Of LYMPHIR BLA Resubmission Citius to resubmit marketing application for lymphoma candidate in 2024 Citius gains as pivotal trial for antibiotic hits key milestone Seek...

2023-09-28 06:20:30 ET Summary Citius Pharmaceuticals is a late-stage biotech with a drug to treat lymphoma, but their cash runway is not long enough for FDA approval. Their flagship drug, Lymphir, has shown promising results in a study, but it is a different version of a previous...

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...

Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023 PR Newswire CRANFORD, N.J. , Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage bi...

Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir PR Newswire CRANFORD, N.J. , Sept. 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir , w...

2023-09-08 09:05:46 ET More on Citius Seeking Alpha’s Quant Rating on Citius Pharmaceuticals Historical earnings data for Citius Pharmaceuticals Financial information for Citius Pharmaceuticals Citius gains as pivotal trial for antibiotic hits key mile...

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™ PR Newswire Resubmission to FDA planned for early 2024 CRANFORD, N.J. , Sept. 8, 2023 ...

Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 PR Newswire CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopha...